EA037712B1 - Кардио- и нефропротективная противодиабетическая терапия - Google Patents

Кардио- и нефропротективная противодиабетическая терапия Download PDF

Info

Publication number
EA037712B1
EA037712B1 EA201500934A EA201500934A EA037712B1 EA 037712 B1 EA037712 B1 EA 037712B1 EA 201500934 A EA201500934 A EA 201500934A EA 201500934 A EA201500934 A EA 201500934A EA 037712 B1 EA037712 B1 EA 037712B1
Authority
EA
Eurasian Patent Office
Prior art keywords
patients
disease
linagliptin
patient
renal
Prior art date
Application number
EA201500934A
Other languages
English (en)
Russian (ru)
Other versions
EA201500934A1 (ru
Inventor
Одд-Эрик Йёханзен
Максимилиан Фон-Эйнаттен
Томас Клайн
Ханс-Йюрген Вёрле
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50277246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA037712(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201500934A1 publication Critical patent/EA201500934A1/ru
Publication of EA037712B1 publication Critical patent/EA037712B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA201500934A 2013-03-15 2014-03-14 Кардио- и нефропротективная противодиабетическая терапия EA037712B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13159624 2013-03-15
EP13177311 2013-07-19
PCT/EP2014/055113 WO2014140284A1 (en) 2013-03-15 2014-03-14 Use of linagliptin in cardio- and renoprotective antidiabetic therapy

Publications (2)

Publication Number Publication Date
EA201500934A1 EA201500934A1 (ru) 2016-03-31
EA037712B1 true EA037712B1 (ru) 2021-05-13

Family

ID=50277246

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201500934A EA037712B1 (ru) 2013-03-15 2014-03-14 Кардио- и нефропротективная противодиабетическая терапия

Country Status (14)

Country Link
US (9) US20140274889A1 (https=)
EP (4) EP2968344A1 (https=)
JP (4) JP2016510795A (https=)
KR (2) KR20150128726A (https=)
CN (2) CN110075098A (https=)
AU (2) AU2014230096C1 (https=)
BR (1) BR112015020209A2 (https=)
CA (1) CA2903577C (https=)
CL (1) CL2015002369A1 (https=)
EA (1) EA037712B1 (https=)
IL (1) IL240064A0 (https=)
MX (2) MX2015011466A (https=)
PH (1) PH12015502042A1 (https=)
WO (1) WO2014140284A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
JPWO2017170434A1 (ja) * 2016-03-28 2019-01-31 インターセプト ファーマシューティカルズ， インコーポレイテッド Ｆｘｒアゴニストとａｒｂの組み合わせ医薬
JP7221694B2 (ja) 2016-04-28 2023-02-14 ノヴォ ノルディスク アー／エス 心血管状態におけるセマグルチド
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
WO2020016230A1 (en) * 2018-07-17 2020-01-23 Boehringer Ingelheim International Gmbh Cardio- and renosafe antidiabetic therapy
WO2020016232A1 (en) * 2018-07-17 2020-01-23 Boehringer Ingelheim International Gmbh Cardiosafe antidiabetic therapy
JP7227380B2 (ja) * 2018-12-18 2023-02-21 武漢人福創新薬物研発中心有限公司 フェニルピロリジン化合物及びその用途
WO2022244846A1 (ja) * 2021-05-19 2022-11-24 Kagami株式会社 細胞増殖の調整のための組成物及び細胞増殖の調整方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012065993A1 (en) * 2010-11-15 2012-05-24 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013171167A1 (en) * 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174768A1 (en) * 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
TW225528B (https=) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
KR100926247B1 (ko) 2001-02-24 2009-11-12 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
EP1532149B9 (de) 2002-08-21 2011-04-20 Boehringer Ingelheim Pharma GmbH & Co. KG 8-[3-amino-piperidin-1-yl] -xanthine, deren herstellung und deren verwendung als arzneimittel
DE10238470A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10238477A1 (de) 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10251927A1 (de) 2002-11-08 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
UY28103A1 (es) 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
DE10327439A1 (de) 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE10359098A1 (de) 2003-12-17 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
DE10360835A1 (de) 2003-12-23 2005-07-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
JP4733058B2 (ja) 2004-02-18 2011-07-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ８−［３−アミノ−ピペリジン−１−イル］−キサンチン、その製造及びそのｄｐｐ−ｉｖインヒビターの形態での使用
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
WO2005097798A1 (de) 2004-04-10 2005-10-20 Boehringer Ingelheim International Gmbh Neue 2-amino-imidazo[4,5-d]pyridazin-4-one und 2-amino-imidazo[4,5-c]pyridin-4-one, deren herstellung und deren verwendung als arzneimittel
DE102004022970A1 (de) 2004-05-10 2005-12-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazolderivate, deren Herstellung und deren Verwendung als Intermediate zur Herstellung von Arzneimitteln und Pestiziden
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
JP2008515905A (ja) 2004-10-08 2008-05-15 ノバルティス アクチエンゲゼルシャフト 有機化合物の組合せ剤
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20080318922A1 (en) 2004-12-24 2008-12-25 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic Pyrrole Derivatives
AU2006239929B2 (en) * 2005-04-22 2011-11-03 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
CN102757397A (zh) 2005-07-01 2012-10-31 默沙东公司 合成cetp抑制剂的方法
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1966215A1 (en) 2005-12-23 2008-09-10 Novartis AG Condensed heterocyclic compounds useful as dpp-iv inhibitors
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP2010500326A (ja) 2006-08-08 2010-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病の治療のためのｄｐｐ−ｉｖ阻害剤としてのピロロ［３，２−ｄ］ピリミジン
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32177A (es) * 2008-10-16 2010-05-31 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
SG174504A1 (en) * 2009-03-27 2011-10-28 Bristol Myers Squibb Co Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
JP5662453B2 (ja) * 2009-10-02 2015-01-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物の治療上の使用
KR20240090632A (ko) * 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012065993A1 (en) * 2010-11-15 2012-05-24 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013171167A1 (en) * 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174768A1 (en) * 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERTHOLD HOCHER, CHRISTOPH REICHETZEDER, MARKUS L. ALTER: "Renal and Cardiac Effects of DPP-4 Inhibitors – from Preclinical Development to Clinical Research", KIDNEY AND BLOOD PRESSURE RESEARCH, BASEL, CH, vol. 36, no. 1, 1 February 2012 (2012-02-01), CH, pages 65 - 84, XP055116556, ISSN: 1420-4096, DOI: 10.1159/000339028 *
MARIA ANGELA SORTINO, TIZIANA SINAGRA, PIER LUIGI CANONICO: "Linagliptin: A thorough Characterization beyond Its Clinical Efficacy", FRONTIERS IN ENDOCRINOLOGY, FRONTIERS RESEARCH FOUNDATION, CH, vol. 4, CH, pages 16 - 16-9, XP055116550, ISSN: 1664-2392, DOI: 10.3389/fendo.2013.00016 *
MARTIN HALUZ�K, JAN FROL�K, IVAN RYCHL�K: "Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria", INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, HINDAWI PUBLISHING CORPORATION, US, vol. 35, no. 6, 1 January 2013 (2013-01-01), US, pages 483 - 7, XP055116888, ISSN: 1687-8337, DOI: 10.1155/2013/895102 *
ODD ERIK JOHANSEN;DIETMAR NEUBACHER;MAXIMILIAN VON EYNATTEN;SANJAY PATEL;HANS-JUERGEN WOERLE: "Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme", CARDIOVASC DIABETOLOGY, BIOMED CENTRAL, LONDON, GB, vol. 11, no. 1, 10 January 2012 (2012-01-10), GB, pages 3, XP021130722, ISSN: 1475-2840, DOI: 10.1186/1475-2840-11-3 *
P.-H. GROOP ET AL.: "Effects of the DPP-4 inhibitor linagliptin on albuminuria in patients with type 2 diabetes and diabetic nephropathy", 48TH ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD); BERLIN, DE; 1-5 OCTOBER, 2012, 1 October 2012 (2012-10-01), pages 1-3, XP002707736, Retrieved from the Internet: URL: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=0b0017b9-9e90-4695-b9af-b6870e96a921&cKey=421edb9c-b940-40f0-b282-8e61245561d5&mKey={2DBFCAF7-1539-42D5-8DDA-0A94ABB089E8} [retrieved on 2013-07-29], the whole document *

Also Published As

Publication number Publication date
CA2903577A1 (en) 2014-09-18
EP3409279A1 (en) 2018-12-05
US20180263990A1 (en) 2018-09-20
JP2021095409A (ja) 2021-06-24
US20250025470A1 (en) 2025-01-23
AU2014230096B2 (en) 2019-02-21
EP4364796A3 (en) 2024-07-24
US20160089373A1 (en) 2016-03-31
KR20210099201A (ko) 2021-08-11
NZ710249A (en) 2021-04-30
EP3744327A1 (en) 2020-12-02
CA2903577C (en) 2023-10-17
US20140274889A1 (en) 2014-09-18
EP4364796A2 (en) 2024-05-08
KR20150128726A (ko) 2015-11-18
WO2014140284A1 (en) 2014-09-18
JP2019112409A (ja) 2019-07-11
IL240064A0 (en) 2015-09-24
BR112015020209A2 (pt) 2017-07-18
CN110075098A (zh) 2019-08-02
AU2019203445A1 (en) 2019-06-06
CL2015002369A1 (es) 2016-02-19
US20240033270A1 (en) 2024-02-01
US20210205316A1 (en) 2021-07-08
AU2014230096C1 (en) 2019-08-29
JP2016510795A (ja) 2016-04-11
MX2015011466A (es) 2016-01-22
EP2968344A1 (en) 2016-01-20
US20190192523A1 (en) 2019-06-27
US20170065596A1 (en) 2017-03-09
CN105188706A (zh) 2015-12-23
US20200338086A1 (en) 2020-10-29
PH12015502042B1 (en) 2016-01-18
JP2025115998A (ja) 2025-08-07
EA201500934A1 (ru) 2016-03-31
PH12015502042A1 (en) 2016-01-18
MX2021014242A (es) 2022-01-06
AU2014230096A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
US20250025470A1 (en) Cardio- and renoprotective antidiabetic therapy
US20240156823A1 (en) Vasoprotective and cardioprotective antidiabetic therapy
US20210379073A1 (en) Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
AU2017272209B2 (en) Vasoprotective and cardioprotective antidiabetic therapy
AU2013204252B2 (en) Vasoprotective and cardioprotective antidiabetic therapy
NZ710249B2 (en) Use of linagliptin in cardio- and renoprotective antidiabetic therapy